To include your compound in the COVID-19 Resource Center, submit it here.

Tykerb lapatinib regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against Tyverb lapatinib from GlaxoSmithKline or Herceptin trastuzumab from the Genentech Inc.

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE